Clinical Trial

Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients

Name: Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients — clinical trial record (NCT07017036)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: VBPL-IVIGP3

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The study duration for individual patients will be up to 55 weeks for the 4-weekly and 3- weekly schedule of the treatment which includes 3 weeks for screening, 48 weeks for Study Medication administration and 4 weeks for follow-up assessments

Trial Details

NCT Number	NCT07017036
Lead Sponsor	Virchow Group
Conditions	Primary Immunodeficiency Diseases (PID)
Enrollment	44 participants
Start Date	2025-07-01
Primary Completion	2026-12-01 (estimated)
Study Completion	2026-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-06-12